You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer

Citation Tools

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Lum LG, Al-Kadhimi Z, Deol A, et al
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
Journal for ImmunoTherapy of Cancer 2021;9:e002194. doi: 10.1136/jitc-2020-002194